Strategic Financial Concepts LLC Invests $104,000 in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Strategic Financial Concepts LLC acquired a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 103,508 shares of the medical equipment provider’s stock, valued at approximately $104,000. Strategic Financial Concepts LLC owned about 0.05% of Zimmer Biomet at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Dunhill Financial LLC lifted its position in shares of Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 218 shares during the last quarter. Ashton Thomas Securities LLC bought a new position in shares of Zimmer Biomet in the 3rd quarter valued at approximately $28,000. Brooklyn Investment Group acquired a new stake in Zimmer Biomet in the 3rd quarter worth approximately $35,000. R Squared Ltd bought a new stake in Zimmer Biomet during the fourth quarter worth approximately $63,000. Finally, Mather Group LLC. grew its holdings in Zimmer Biomet by 100.9% during the fourth quarter. Mather Group LLC. now owns 661 shares of the medical equipment provider’s stock valued at $70,000 after purchasing an additional 332 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

ZBH stock opened at $98.98 on Thursday. The company has a current ratio of 1.91, a quick ratio of 0.70 and a debt-to-equity ratio of 0.43. The firm has a market cap of $19.70 billion, a P/E ratio of 22.24, a P/E/G ratio of 1.83 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $133.90. The business’s 50 day moving average is $106.91 and its 200-day moving average is $107.91.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the business earned $2.20 EPS. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.25 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.97%. The ex-dividend date was Monday, December 30th. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Analyst Ratings Changes

A number of analysts have recently weighed in on ZBH shares. Stifel Nicolaus boosted their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. Royal Bank of Canada decreased their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Truist Financial reaffirmed a “hold” rating and issued a $113.00 price target (down from $118.00) on shares of Zimmer Biomet in a research report on Monday. Barclays cut their price objective on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet in a report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.